Carvedilol Inhibits the Exogenous NADH Dehydrogenase in Rat Heart Mitochondria

Detalhes bibliográficos
Autor(a) principal: Oliveira, Paulo J.
Data de Publicação: 2000
Outros Autores: Santos, Dario J., Moreno, António J. M.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10316/3895
https://doi.org/10.1006/abbi.1999.1624
Resumo: There are several reports on the oxidation of external NADH by an exogenous NADH dehydrogenase in the outer leaflet of the inner membrane of rat heart mitochondria. Until now, however, little was known about its physiological role in cellular metabolism. The present work shows that carvedilol ({1-[carbazolyl-(4)-oxy]-3-[2-methoxyphenoxyethyl)amino]-pro- panol-(2)}) is a specific inhibitor of an exogenous NADH dehydrogenase in rat heart mitochondria. Carvedilol does not affect oxygen consumption linked to the oxidation of succinate and internal NADH. It is also demonstrated that the inhibition of exogenous NADH dehydrogenase by carvedilol is accompanied by the inhibition of alkalinization of the external medium. In contrast to the addition of glutamate/malate or succinate, exogenous NADH does not generate a membrane potential in rat heart mitochondria, as observed with a TPP+ electrode. It is also demonstrated that the oxygen consumption linked to NADH oxidation is not due to permeabilized mitochondria, but to actual oxidase activity in the inner membrane. The enzyme has a Km for NADH of 13 [mu]M. Carvedilol is a noncompetitive inhibitor of this external NADH dehydrogenase with a Ki of 15 [mu]M. Carvedilol is the first inhibitor described to this organospecific enzyme. Since this enzyme was demonstrated to play a key role in the cardiotoxicity of anticancer drugs of the anthracycline family (e.g., adriamycin), we may suggest that the administration of carvedilol to tumor patients treated with adriamycin might be of great help in the prevention of the cardioselective toxicity of this antibiotic.
id RCAP_ad0698fb3ca87526ca2c2c6ade3cde5e
oai_identifier_str oai:estudogeral.uc.pt:10316/3895
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Carvedilol Inhibits the Exogenous NADH Dehydrogenase in Rat Heart Mitochondriarat heart mitochondria; exogenous NADH dehydrogenase; inhibitor; carvedilolThere are several reports on the oxidation of external NADH by an exogenous NADH dehydrogenase in the outer leaflet of the inner membrane of rat heart mitochondria. Until now, however, little was known about its physiological role in cellular metabolism. The present work shows that carvedilol ({1-[carbazolyl-(4)-oxy]-3-[2-methoxyphenoxyethyl)amino]-pro- panol-(2)}) is a specific inhibitor of an exogenous NADH dehydrogenase in rat heart mitochondria. Carvedilol does not affect oxygen consumption linked to the oxidation of succinate and internal NADH. It is also demonstrated that the inhibition of exogenous NADH dehydrogenase by carvedilol is accompanied by the inhibition of alkalinization of the external medium. In contrast to the addition of glutamate/malate or succinate, exogenous NADH does not generate a membrane potential in rat heart mitochondria, as observed with a TPP+ electrode. It is also demonstrated that the oxygen consumption linked to NADH oxidation is not due to permeabilized mitochondria, but to actual oxidase activity in the inner membrane. The enzyme has a Km for NADH of 13 [mu]M. Carvedilol is a noncompetitive inhibitor of this external NADH dehydrogenase with a Ki of 15 [mu]M. Carvedilol is the first inhibitor described to this organospecific enzyme. Since this enzyme was demonstrated to play a key role in the cardiotoxicity of anticancer drugs of the anthracycline family (e.g., adriamycin), we may suggest that the administration of carvedilol to tumor patients treated with adriamycin might be of great help in the prevention of the cardioselective toxicity of this antibiotic.http://www.sciencedirect.com/science/article/B6WB5-45KKS8V-J4/1/9866d8c0259a7564856d6a5679c9fafc2000info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleaplication/PDFhttp://hdl.handle.net/10316/3895http://hdl.handle.net/10316/3895https://doi.org/10.1006/abbi.1999.1624engArchives of Biochemistry and Biophysics. 374:2 (2000) 279-285Oliveira, Paulo J.Santos, Dario J.Moreno, António J. M.info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2021-10-22T08:35:07Zoai:estudogeral.uc.pt:10316/3895Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T20:55:43.389273Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Carvedilol Inhibits the Exogenous NADH Dehydrogenase in Rat Heart Mitochondria
title Carvedilol Inhibits the Exogenous NADH Dehydrogenase in Rat Heart Mitochondria
spellingShingle Carvedilol Inhibits the Exogenous NADH Dehydrogenase in Rat Heart Mitochondria
Oliveira, Paulo J.
rat heart mitochondria; exogenous NADH dehydrogenase; inhibitor; carvedilol
title_short Carvedilol Inhibits the Exogenous NADH Dehydrogenase in Rat Heart Mitochondria
title_full Carvedilol Inhibits the Exogenous NADH Dehydrogenase in Rat Heart Mitochondria
title_fullStr Carvedilol Inhibits the Exogenous NADH Dehydrogenase in Rat Heart Mitochondria
title_full_unstemmed Carvedilol Inhibits the Exogenous NADH Dehydrogenase in Rat Heart Mitochondria
title_sort Carvedilol Inhibits the Exogenous NADH Dehydrogenase in Rat Heart Mitochondria
author Oliveira, Paulo J.
author_facet Oliveira, Paulo J.
Santos, Dario J.
Moreno, António J. M.
author_role author
author2 Santos, Dario J.
Moreno, António J. M.
author2_role author
author
dc.contributor.author.fl_str_mv Oliveira, Paulo J.
Santos, Dario J.
Moreno, António J. M.
dc.subject.por.fl_str_mv rat heart mitochondria; exogenous NADH dehydrogenase; inhibitor; carvedilol
topic rat heart mitochondria; exogenous NADH dehydrogenase; inhibitor; carvedilol
description There are several reports on the oxidation of external NADH by an exogenous NADH dehydrogenase in the outer leaflet of the inner membrane of rat heart mitochondria. Until now, however, little was known about its physiological role in cellular metabolism. The present work shows that carvedilol ({1-[carbazolyl-(4)-oxy]-3-[2-methoxyphenoxyethyl)amino]-pro- panol-(2)}) is a specific inhibitor of an exogenous NADH dehydrogenase in rat heart mitochondria. Carvedilol does not affect oxygen consumption linked to the oxidation of succinate and internal NADH. It is also demonstrated that the inhibition of exogenous NADH dehydrogenase by carvedilol is accompanied by the inhibition of alkalinization of the external medium. In contrast to the addition of glutamate/malate or succinate, exogenous NADH does not generate a membrane potential in rat heart mitochondria, as observed with a TPP+ electrode. It is also demonstrated that the oxygen consumption linked to NADH oxidation is not due to permeabilized mitochondria, but to actual oxidase activity in the inner membrane. The enzyme has a Km for NADH of 13 [mu]M. Carvedilol is a noncompetitive inhibitor of this external NADH dehydrogenase with a Ki of 15 [mu]M. Carvedilol is the first inhibitor described to this organospecific enzyme. Since this enzyme was demonstrated to play a key role in the cardiotoxicity of anticancer drugs of the anthracycline family (e.g., adriamycin), we may suggest that the administration of carvedilol to tumor patients treated with adriamycin might be of great help in the prevention of the cardioselective toxicity of this antibiotic.
publishDate 2000
dc.date.none.fl_str_mv 2000
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10316/3895
http://hdl.handle.net/10316/3895
https://doi.org/10.1006/abbi.1999.1624
url http://hdl.handle.net/10316/3895
https://doi.org/10.1006/abbi.1999.1624
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Archives of Biochemistry and Biophysics. 374:2 (2000) 279-285
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv aplication/PDF
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799133843724173312